Antibodies News and Research

RSS

AI-created miniproteins show promise for targeting hard-to-treat diseases

G protein-coupled receptors, or GPCRs, sit in the plasma membrane, the boundary that defines the inside and outside of a living cell. They communicate with nearly every physiological process in our bodies - from the ability to see and smell, to sensing of adrenaline, insulin, nutrients and medicines.

21 May 2026

New immuno-infrared sensor aids in early diagnosis of Alzheimer’s and Parkinson’s disease

An early start to treatment is crucial to successful therapy. A new sensor is helping with early detection.

21 May 2026

Polymer-based immunotherapies enhance tumor targeting and immune activation

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less than 30% of patients.

21 May 2026

Rerouting dead tumor debris enhances cancer immunotherapy outcomes

As tumors outgrow their blood and nutrient supplies, or respond to treatments like chemotherapy and radiotherapy, individual cancer cells die, exposing their internal scaffolds.

20 May 2026

Engineered nanomaterials optimize delivery barriers in cancer immunotherapy

Cancer immunotherapy works by mobilizing the body's own immune system to recognize and destroy malignant cells.

20 May 2026

Sino Biological launches XPressMAX™ Cell-Free Protein Synthesis Kit, accelerating AI-powered high-throughput antibody drug discovery

Sino Biological, Inc., a global leader in recombinant technology, is proud to announce the launch of its innovative XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02) , a cutting-edge solution designed to supercharge artificial intelligence (AI)-driven high-throughput screening pipelines for antibody drug discovery.

From Sino Biological Inc. 20 May 2026

Ensitrelvir cuts household COVID-19 risk when given after exposure

Ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor, reduced symptomatic RT-PCR-confirmed COVID-19 among household contacts when given within 72 hours after symptom onset in the infected index patient. In the phase 3 SCORPIO-PEP trial, COVID-19 occurred in 2.9% of ensitrelvir recipients versus 9.0% of placebo recipients, with similar overall adverse-event rates.

20 May 2026

How antibody-drug conjugates are redefining targeted cancer therapy

Antibody-drug conjugates are rapidly expanding cancer therapies, with 19 approved globally and many more in development, but their success depends on better targets, payloads, linkers, dosing, and patient selection. The Cell review shows that next-generation ADCs could widen treatment options, but safety, resistance, tumor heterogeneity, and clinical translation remain major barriers.

19 May 2026

Identifying the methodology gap that prevents treatment of infection-triggered chronic diseases

Thousands of Americans develop chronic persistent symptoms-such as fatigue, cognitive difficulties ("brain fog"), and other debilitating issues-each year following acute infections from Lyme disease, COVID-19, and other pathogens. Efforts to identify causes and produce treatments have failed. However, 16 leading researchers think they know part of the problem: study design.

14 May 2026

Battery-free wearable sensor continuously monitors health through sweat

University of California, Irvine researchers have invented a wearable, wireless, battery-free, bioelectronic sensor to monitor users' health by analyzing molecular biomarkers in human sweat.

13 May 2026

Next-generation cancer therapy shows early promise as treatment candidate for glioblastoma

A next-generation cancer therapy being developed at McMaster University has shown early promise as a treatment candidate for glioblastoma, the most aggressive and most common type of primary brain cancer in adults.

13 May 2026

New mRNA adjuvant dramatically boosts T-cell vaccine responses in mice

MIT engineers have developed a new way to amplify the T-cell response to mRNA vaccines - an advance that could lead to much more powerful cancer vaccines and stronger protection against infectious diseases.

13 May 2026

Antibodies targeting GPNMB may slow Parkinson's disease progression

Monoclonal antibodies can block a key immune‑related protein that drives the spread of brain cell damage in Parkinson's disease (PD).

12 May 2026

Nuclera launches antibody triage service to advance AI-driven antibody discovery

Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its antibody screening service to streamline the transition from antibody hit generation to lead selection.

From Nuclera 11 May 2026

Rockefeller scientists reveal how HIV strains escape broadly neutralizing antibodies

Broadly neutralizing antibodies (bNAbs) are among the most promising new treatments for HIV, offering the potential to forego traditional daily dose of antiretroviral drugs.

11 May 2026

Slow and steady wins: Low-dose peanut immunotherapy safely desensitizes 82% of preschoolers in landmark trial

A Swedish randomized trial found that slow up-dosing peanut oral immunotherapy with a low maintenance dose helped 82% of preschool children achieve sustained peanut tolerance after three years. The approach proved safer than conventional protocols, with severe reactions uncommon and strong family adherence throughout treatment.

10 May 2026